Molecular Principle of Topotecan Resistance by Topoisomerase I Mutations through Molecular Modeling Approaches

Originally isolated from natural products, camptothecin (CPT) has provided extensive playing fields for the development of antitumor drugs. Two of the most successful analogs of CPT, topotecan and irinotecan, have been approved by the FDA for the treatment of colon cancer and ovarian cancer, as well as other cancers. However, the emergence of drug resistance mutations in topoisomerase I is a big challenge for the effective therapy of these drugs. Therefore, in this study, a series of computational approaches from molecular dynamics (MD) simulations to steered molecular dynamics (SMD) simulations and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) binding free energy calculations were employed to uncover the molecular principle of the topotecan resistance induced by three mutations in DNA topoisomerase I, including E418K, G503S, and D533G. Our results demonstrate a remarkable correlation between the binding free energies predicted by MM/GBSA and the rupture forces computed by SMD, and moreover, the theoretical results given by MM/GBSA and SMD are in excellent agreement with the experimental data for ranking the inhibitory activities: WT > E418K > G503S > D533G. In order to explore the drug resistance mechanism that underlies the loss of the binding affinity of topotecan, the binding modes of topotecan bound to the WT and mutated receptors were presented, and comparisons of the binding geometries and energy contributions on a per residue basis of topotecan between the WT complex and each mutant were also discussed. The results illustrate that the mutations of E418K, G503S, and D533G have great influence on the binding of topotecan to topoisomerase I bound with DNA, and the variations of the polar interactions play critical roles in the development of drug resistance. The information obtained from this study provides useful clues for designing improved topoisomerase I inhibitors for combating drug resistance.

[1]  N. Saijo,et al.  Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. , 1992, Biochemical and biophysical research communications.

[2]  Y. Pommier,et al.  Topoisomerase I-mediated DNA damage. , 2001, Advances in cancer research.

[3]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[4]  Gottlieb Ja,et al.  Treatment of malignant melanoma with camptothecin (NSC-100880). , 1972 .

[5]  N. Hanna,et al.  Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer , 2008 .

[6]  J. Champoux,et al.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. , 1998, Science.

[7]  Tingjun Hou,et al.  Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking , 2011, J. Comput. Chem..

[8]  Yves Pommier,et al.  Camptothecin-resistant Human Prostate Cancer Cell Line Characterization of a Novel Topoisomerase I Mutation from a Updated Version , 2001 .

[9]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[10]  Tingjun Hou,et al.  Structural Bioinformatics Prediction of Peptides Binding to the Pka Riiα Subunit Using a Hierarchical Strategy , 2022 .

[11]  Huanxiang Liu,et al.  In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase. , 2010, Molecular pharmaceutics.

[12]  Y. Pommier,et al.  Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. , 1992, Cancer research.

[13]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[14]  Mai Suan Li,et al.  Top Leads for Swine Influenza A/H1N1 Virus Revealed by Steered Molecular Dynamics Approach , 2010, J. Chem. Inf. Model..

[15]  P. Pantazis,et al.  Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. , 1997, Cancer research.

[16]  Giovanni Chillemi,et al.  Thr 729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations , 2008 .

[17]  Y. Pommier,et al.  Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. , 1995, Cancer research.

[18]  L. Liu,et al.  Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. , 1997, Biochemical pharmacology.

[19]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[20]  Huanxiang Liu,et al.  Understanding the effect of drug-resistant mutations of HIV-1 intasome on raltegravir action through molecular modeling study. , 2012, Molecular bioSystems.

[21]  Lin Li,et al.  Understanding microscopic binding of macrophage migration inhibitory factor with phenolic hydrazones by molecular docking, molecular dynamics simulations and free energy calculations. , 2012, Molecular bioSystems.

[22]  D. Case,et al.  Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain. , 2008, Journal of molecular biology.

[23]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[24]  Jang-Yang Chang,et al.  Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. , 2002, Cancer research.

[25]  Peter A. Kollman,et al.  Computational alanine scanning of the 1:1 human growth hormone–receptor complex , 2002, J. Comput. Chem..

[26]  Christopher Poole,et al.  Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Weiliang Zhu,et al.  Dynamic mechanism of E2020 binding to acetylcholinesterase: a steered molecular dynamics simulation. , 2005, The journal of physical chemistry. B.

[28]  William A. McLaughlin,et al.  Evaluating the potency of HIV‐1 protease drugs to combat resistance , 2008, Proteins.

[29]  U Schaeppi,et al.  Toxicity of camptothecin (NSC-100880). , 1974, Cancer chemotherapy reports. Part 3.

[30]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[31]  Jin Qin,et al.  Molecular Dynamics Simulation, Free Energy Calculation and Structure-Based 3D-QSAR Studies of B-RAF Kinase Inhibitors , 2011, J. Chem. Inf. Model..

[32]  J. Wang,et al.  Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. , 1993, Cancer research.

[33]  Wei Wang,et al.  Characterization of domain-peptide interaction interface: prediction of SH3 domain-mediated protein-protein interaction network in yeast by generic structure-based models. , 2012, Journal of proteome research.

[34]  Giovanni Chillemi,et al.  Single Mutation in the Linker Domain Confers Protein Flexibility and Camptothecin Resistance to Human Topoisomerase I* , 2003, Journal of Biological Chemistry.

[35]  D. Case,et al.  Modification of the Generalized Born Model Suitable for Macromolecules , 2000 .

[36]  Eileen M O'Reilly,et al.  Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Eric Patterson,et al.  Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites , 1991, Nucleic Acids Res..

[38]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[39]  Lance Stewart,et al.  The mechanism of topoisomerase I poisoning by a camptothecin analog , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Lin Li,et al.  Theoretical Studies on the Susceptibility of Oseltamivir against Variants of 2009 A/H1N1 Influenza Neuraminidase , 2012, J. Chem. Inf. Model..

[41]  R J Reitemeier,et al.  Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. , 1972, Cancer chemotherapy reports.

[42]  P. Kollman,et al.  Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. , 2000, Journal of medicinal chemistry.

[43]  Lirong Chen,et al.  Mapping the Binding Site of a Large Set of Quinazoline Type EGF-R Inhibitors Using Molecular Field Analyses and Molecular Docking Studies. , 2003 .

[44]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[45]  B. Kuhn,et al.  Validation and use of the MM-PBSA approach for drug discovery. , 2005, Journal of medicinal chemistry.

[46]  Giovanni Chillemi,et al.  Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations , 2008, Nucleic acids research.

[47]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[48]  Jörg Weiser,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999, J. Comput. Chem..

[49]  J A Gottlieb,et al.  Treatment of malignant melanoma with camptothecin (NSC-100880). , 1972, Cancer chemotherapy reports.

[50]  D. Case,et al.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. , 2003, Journal of molecular biology.

[51]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.

[52]  Y. Pommier,et al.  Substitutions of Asn-726 in the Active Site of Yeast DNA Topoisomerase I Define Novel Mechanisms of Stabilizing the Covalent Enzyme-DNA Intermediate* , 2000, The Journal of Biological Chemistry.

[53]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .

[54]  Jing Zhang,et al.  Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance , 2010, Proceedings of the National Academy of Sciences.

[55]  A. Fojo,et al.  Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. , 1997, Cancer research.

[56]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[58]  Gianfranco Pasut,et al.  PEG conjugates in clinical development or use as anticancer agents: an overview. , 2009, Advanced drug delivery reviews.

[59]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[60]  Yves Pommier,et al.  Mechanisms of camptothecin resistance by human topoisomerase I mutations. , 2004, Journal of molecular biology.

[61]  Y. Pommier,et al.  Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. , 2001, Cancer research.

[62]  D. Heo,et al.  Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  D. J. Clarke,et al.  DNA Topoisomerases , 2009, Methods in Molecular Biology™.

[64]  M. Bjornsti,et al.  Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. , 1999, Molecular pharmacology.

[65]  D. Kufe,et al.  Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. , 1994, The Journal of biological chemistry.

[66]  Mai Suan Li,et al.  Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach. , 2011, Biochemical and biophysical research communications.

[67]  Jaroslav Koca,et al.  CAVER: a new tool to explore routes from protein clefts, pockets and cavities , 2006, BMC Bioinformatics.

[68]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[69]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[70]  Y. Pommier,et al.  Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. , 1993, The Journal of biological chemistry.

[71]  Huanxiang Liu,et al.  Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. , 2012, Antiviral research.

[72]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[73]  B. Monk,et al.  Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study , 2006 .